New hope for fighting breast cancer in the bones
NCT ID NCT06374459
Summary
This study is testing a new drug, zunsemetinib, combined with the standard chemotherapy capecitabine, for people with a specific type of advanced breast cancer that has spread to the bones. The main goals are to find a safe and effective dose and to see if the combination can help control the cancer and slow its growth. It is for adults whose cancer has progressed despite prior hormone therapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HORMONE RECEPTOR POSITIVE HER-2 NEGATIVE METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mayo Clinic
NOT_YET_RECRUITINGRochester, Minnesota, 55905, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The University of Kansas Cancer Center
RECRUITINGWestwood, Kansas, 66205, United States
Contact Phone: •••-•••-••••
Contact
-
Washington University School of Medicine
RECRUITINGSt Louis, Missouri, 63110, United States
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.